Trade Vir Biotechnology VIR

VirBiotechnology live chart

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

VirBiotechnology news

Mga pinakabagong balita

Ipakita nang marami
Tommy Yap 2025 Mayo 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 Mayo 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds
Frances Wang 2025 Mayo 08, 16:00

Bond Market News Today: Alphabet (GOOGL) Back to Corporate Bond Market

Bonds
Frances Wang 2025 Mayo 08, 16:00

Tariffs News Update: How Trump’s Policies Affect Bond Market?

Bonds
Tommy Yap 2025 Mayo 08, 16:00

Morning Note: Dollar Climbs on Trade Winds; BTC Soars; ECB's Dovish Tone

Morning Note Forex Cryptocurrencies
Frances Wang 2025 Mayo 07, 16:00

Stock Market Today: Dow Jones Up, Nvidia stock fluctuates, Nasdaq Rises

Stocks Indices NVDA
Tommy Yap 2025 Mayo 07, 16:00

Morning Note: BoE Rate Cut?, US Jobs, Toyota Earnings Today

Morning Note USD GBP
Frances Wang 2025 Mayo 06, 16:00

Trending forex pairs: EUR/USD Fluctuates, USD/TWD Drops, AUD/JPY Rises

Forex

Info

Spread

0.05

Spread (%)

0.9785 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Biyernes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

702055424

Natitirang Pagbabahagi

138064000

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

Araw ng Pag-alis ng Karapatan sa Dividend

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-4.23

Alamin ang Higit Pa Tungkol sa Instrumentong ito

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Mga kaugnay na instrumento

view_all_instruments

latest_education_articles

Ipakita nang marami
Trustpilot